Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.
Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.
Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.
Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.
Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.
Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.
Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.
Abbott (NYSE: ABT) has won three CES 2023 Innovation Awards from the Consumer Technology Association for its innovative health technologies. The awarded products include the Aveir VR Leadless Pacemaker, the Proclaim Plus SCS System, and the Alinity m Monkeypox PCR test. Abbott's achievements continue as the company was previously recognized for its FreeStyle Libre technology, named the best medical technology of the last 50 years by the Galien Foundation. This recognition underscores Abbott's commitment to advancing healthcare solutions globally.
Surmodics announced positive results from the 24-month follow-up of its TRANSCEND clinical trial at the VIVA conference in Las Vegas. The study involved 446 patients and compared the SurVeil DCB with the leading IN.PACT Admiral DCB. Results show that SurVeil achieved a primary patency rate of 70.8% versus 70.4% for IN.PACT, with comparable safety profiles. SurVeil uses a significantly lower dose of paclitaxel, which may enhance patient outcomes. Surmodics holds a partnership with Abbott (ABT) for commercialization upon FDA approval.
Surmodics, Inc. (NASDAQ:SRDX) announced that findings from the TRANSCEND clinical trial will be shared at the Vascular InterVentional Advances (VIVA) conference on November 1, 2022. Dr. Kenneth Rosenfield will present 24-month data on the efficacy and safety of the SurVeil drug-coated balloon (DCB) compared to IN.PACT Admiral DCB. Initial results at 12 months indicated non-inferiority for SurVeil with a lower drug dose. Surmodics has an agreement with Abbott (NYSE: ABT) for commercialization rights.
Abbott's third-quarter sales reached $10.4 billion with a 4.7% decline on a reported basis but a 1.3% increase organically. GAAP EPS was $0.81, while adjusted EPS surged to $1.15. Abbott raised its full-year 2022 EPS guidance to $3.75-$3.81 (GAAP) and $5.17-$5.23 (adjusted). Strong growth was noted in U.S. Medical Devices, particularly in Electrophysiology, Structural Heart, and Diabetes Care. The launch of FreeStyle Libre 3 boosted sales, despite declines in Nutrition and Diagnostics due to past manufacturing issues and diminished COVID-19 testing revenue.
Abbott (NYSE: ABT) has partnered with The Home Edit to redesign medicine cabinets in preparation for the flu and virus season, which is impacted by COVID-19. The initiative focuses on organizing health essentials like the BinaxNOW COVID-19 Antigen Self Test, enhancing family preparedness. With over a billion BinaxNOW tests produced, Abbott emphasizes the importance of at-home testing for quick results. The Home Edit offers organizational tips to help families maintain essential items efficiently and visually appeal to their health space.
A recent study published in The New England Journal of Medicine demonstrates that Abbott's FreeStyle Libre 2 glucose monitoring system significantly lowers glycated hemoglobin (HbA1c) levels in adults with Type 1 diabetes compared to self-monitoring of blood glucose (SMBG). At the end of the 24-week study, FreeStyle Libre users exhibited a 0.5% reduction in HbA1c, while SMBG users only saw a 0.2% decrease. The study also noted improvements in quality of life and greater treatment satisfaction among FreeStyle Libre users.
Abbott will announce its third-quarter 2022 financial results on October 19, 2022, prior to market opening. The earnings conference call will take place at 8 a.m. Central time and will be accessible via Abbott's Investor Relations website. Abbott operates globally, providing technologies in diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries with a workforce of 113,000 colleagues.
Abbott (NYSE: ABT) announced significant findings from five late-breaking presentations at the TCT 2022, showcasing its minimally invasive structural heart devices. Key highlights include the MitraClip's efficacy in treating mitral regurgitation, achieving a 91% success rate in MR reduction with low adverse event rates. The TriClip also showed promising results with a 99% implant success rate. Additionally, the Amulet LAA Occluder demonstrated better stroke reduction compared to competing devices. These advancements reinforce Abbott's leadership in innovative cardiac treatments.
FAQ
What is the current stock price of Abbott Laboratories (ABT)?
What is the market cap of Abbott Laboratories (ABT)?
What does Abbott Laboratories specialize in?
What are some of Abbott’s recent product launches?
How much of Abbott’s sales are generated outside the United States?
What is Abbott’s PROTALITY™ brand?
How does Abbott support global health initiatives?
What is Abbott’s financial performance like?
How many employees does Abbott have?
Which continuous glucose monitoring system is Abbott known for?
What is Abbott's mission?
In how many countries does Abbott operate?
